Back to search

A three-part, phase I, dose-escalation study of GSK1120212, a potent MEK inhibitor, administered orally to subjects with solid tumors or lymphoma

Dawn Thompson, K. T. Flaherty, W. Messersmith, K. Harlacker, Sujatha Nallapareddy
DOI: 10.1200/jco.2009.27.15_suppl.e14584
Journal of Clinical Oncology

Data up to Jan 2025

Published2009
Citations13
References0
Fields
MedicineBiologyInternal medicineGastroenterologyPharmacology

Total Citations Per Year

Abstract

References (0)

No references found

Cited By (0)

Loading...
A three-part, phase I, dose-escalation study of GSK1120212, a potent MEK inhibitor,… (2009) – Journal of Clinical Oncology | Metascience Observatory Explorer